

Our Mission

The mission of Friends of FSH Research is to accelerate the discoveries that will lead to treatments or cures for FSH Muscular Dystrophy



Our Vision


That one day when FSH Muscular Dystrophy is diagnosed, the next words said are... "there is a treatment!"

2024-25 Annual Report

June 1, 2024 - May 31, 2025

Friends funds a record \$1.3M in Research Grants!

Our 2025 Gala in February, “*All In for a Cure*,” raised nearly \$570,000 for FSHD research. These funds, along with funds from other years, were quickly invested in research projects across the globe, including The Fred Hutch Cancer Center in Seattle, the University of Nevada – Reno, Leiden University in the Netherlands, Nationwide Children’s Hospital - Ohio, Newcastle University and King’s College in England, Aix-Marseille University – France, and biotech companies Histone Therapeutics and Talus Biosciences. Grants totaling nearly \$1,300,000 were awarded by *Friends* in the fiscal year ending on May 31, 2025.



These achievements are a direct result of your support as a sponsor or donor, allowing us to continue to fund research that has the best chance of moving toward a treatment or cure at a faster pace and keeps researchers working in the face of funding cuts from federal organizations such as the National Institutes of Health.

Thank you for choosing to invest with us to help improve the lives of those living with FSHD – a disease that slowly destroys skeletal muscles in over half a million women and men around the world.


2024-25 Financial Summary

June 1, 2024 to May 31, 2025

In the fiscal year ending May 31, 2024, Friends of FSH Research:

- Invested \$1,296,506 in 19 FSHD research projects in pursuit of a treatment or cure
- Continued support of novel research projects that may speed discoveries
- Continued support of the FSHD Clinical Trials Research Network and future clinical trials

Thanks to the support of our sponsors and donors, the future is looking more hopeful than ever - a therapy is close at hand for families living with the debilitating effects of FSHD.



Balance Sheet as of May 31, 2025

Year-End Assets	\$433,806
Year-End Liabilities	<u>\$900,308¹</u>

¹ Funds committed to multi-year research projects.

Board of Directors

Terry Colella – President
Rick Colella – Treasurer
Elizabeth Jas
Erik Svenson

Brad Bagshaw – Vice President
Lynn Fischer
Shelli Kind
Karl Voss

George Shaw – Secretary
Chris Haven
Amanda Rickard

Scientific Advisory Board

Jeffrey S. Chamberlain, PhD – Director
Monica Hayhurst Bennett, PhD
Gregory J. Block, MSc, PhD
Silvère M. van der Maarel, PhD

Jamshid Arjomand, PhD
Dennis W. Shaw, MD
Bruce M. Wentworth, PhD

Amanda Rickard, BS
Jeffery Statland, MD
Kyoko Yokomori, PhD